id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-028907-m9psxg1f	Li, Yi	Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for ACS patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double blinded, placebo controlled randomized trial	2020-07-09		.txt	text/plain	3535	165	42	BACKGROUND: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the cornerstone for prevention ischemic events in patients with acute coronary syndromes (ACS) and undergoing percutaneous coronary intervention (PCI). J o u r n a l P r e -p r o o f 3 / 21 Background Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is the cornerstone to prevent stent thrombosis and atherothrombotic events in patients with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary intervention (PCI) [1] [2] [3] . In order to test this hypothesis, we designed the Optimal antiPlatelet Therapy for high Bleeding and Ischemic RISK patients (OPT-BIRISK) trial, to determine if extended clopidogrel monotherapy will be superior to DAPT with clopidogrel and aspirin following completion of 9 to 12 months DAPT for ACS patients who received drug eluting stent (DES) implantation and possess both high bleeding and high ischemic characteristics.	./cache/cord-028907-m9psxg1f.txt	./txt/cord-028907-m9psxg1f.txt